Targeting molecules that downregulate the T cell immune response with immunotherapy such as anti-CTLA-4 (cytotoxic T-lymphocyte antigen-4) or anti-PD-1/PD-L1 (programmed death-1 and it ligands) is currently being assessed in patients with recurrent/metastatic cervical cancer (NCT01693783; NCT02257528; NCT01975831). Here, CD274 is linked to cervical carcinoma.